Monte Rosa Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Monte Rosa Therapeutics

04/08/2025 13:54

Monte Rosa Therapeutics Inc GLUE.OQ GLUE.O is expected to  show a rise in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

The Boston Massachusetts-based  company is expected to report a 130.0% increase in revenue to $10.8 million from $4.7 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Monte Rosa Therapeutics Inc is for a loss of 39 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Monte Rosa Therapeutics Inc is $17.00, about 71.8% above its last closing price of $4.79

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.29
-0.34
0.56
Beat
266.2
Dec. 31 2025
-0.02
0.23
Beat
1,100
Sep. 30 2024
-0.46
-0.49
-0.29
Beat
40.4​
Jun. 30 2024
-0.53
-0.54
-0.43
Beat
20.4
​​Mar. 31 2024
-0.57
-0.57
-0.53
Beat
7.5
Dec. 31 2023
-0.30
-0.33
-0.58
Missed
-73.3​
Sep. 30 2023
-0.72
-0.72
-0.70
Beat
3.3
Jun. 30 2023
-0.69
-0.70
-0.71
Missed
-1.4

This summary was machine generated August 4 at 12:54 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)